Ventyx biosciences announces initiation of dosing in a phase 1 trial of vtx3232, a novel cns-penetrant nlrp3 inhibitor

Topline data from the phase 1 sad/mad trial of vtx3232 are expected in h1 2024 topline data from the phase 1 sad/mad trial of vtx3232 are expected in h1 2024

VTYX Ratings Summary

VTYX Quant Ranking